Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.
Authors
- Jennifer Ann Woyach (ORCID: https://orcid.org/0000-0002-3403-9144)
- Ching Ching Leow
- Catherine C. Coombs (ORCID: https://orcid.org/0000-0003-4656-7304)
- Lugui Qiu (ORCID: https://orcid.org/0000-0002-8752-0644)
- Paula Cramer (ORCID: https://orcid.org/0000-0003-4046-9922)
- Katharine L. Lewis (ORCID: https://orcid.org/0000-0003-0549-5877)
- Marisa Hill
- Tomasz Wróbel (ORCID: https://orcid.org/0000-0002-6612-3535)
- Shuhua Yi (ORCID: https://orcid.org/0000-0002-6291-812X)
- Lutz Jacobasch (ORCID: https://orcid.org/0000-0001-7519-8830)
- Ross Baker (ORCID: https://orcid.org/0000-0002-2728-6788)
- Naleen Raj Bhandari (ORCID: https://orcid.org/0000-0002-4452-8021)
- Katherine Bao (ORCID: https://orcid.org/0000-0001-5377-2387)
- Stéphane Leprêtre (ORCID: https://orcid.org/0000-0003-4282-2160)
- Anna Panovská (ORCID: https://orcid.org/0000-0003-4955-3039)
- Marcelo Capra (ORCID: https://orcid.org/0000-0002-5224-1979)
- Alejandro Berkovits
- Sebastian Grosicki (ORCID: https://orcid.org/0000-0003-2644-1050)
- Richy Agajanian
- Muhıt Özcan (ORCID: https://orcid.org/0000-0002-1326-1918)
- William G. Wierda (ORCID: https://orcid.org/0000-0002-7357-270X)
- Jarosław Czyż (ORCID: https://orcid.org/0000-0002-4178-7837)
- Sílvia Ribeiro (ORCID: https://orcid.org/0000-0002-9996-7857)
- Wojciech J. Jurczak (ORCID: https://orcid.org/0000-0003-1879-8084)
- Kamel Laribi (ORCID: https://orcid.org/0000-0001-5589-7570)
- Ki‐Seong Eom (ORCID: https://orcid.org/0000-0002-0578-126X)
- Yuanyuan Bian (ORCID: https://orcid.org/0000-0003-4736-2597)
- Amy S. Ruppert
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Ankara University (TR)
- Medical University of Silesia (PL)
- Eli Lilly (United States) (US)
- The University of Western Australia (AU)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of California, Irvine (US)
- Masaryk University (CZ)
- Sir Charles Gairdner Hospital (AU)
- Nicolaus Copernicus University (PL)
- Wroclaw Medical University (PL)
- Düsseldorf University Hospital (DE)
- Department of the Premier and Cabinet (AU)
- University Hospital Brno (CZ)
- Centre Hospitalier du Mans (FR)
- Oncology Institute of Hope and Innovation (US)
- Inria Chile (CL)
- Laboratoire National Henri Becquerel (FR)
- Institute of Hematology & Blood Diseases Hospital (CN)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- University Hospital Cologne (DE)
- Orthopädische Praxis (DE)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Hospital Mãe de Deus (BR)
- Heinrich Heine University Düsseldorf (DE)
- The Ohio State University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-12-07
- DOI
- https://doi.org/10.1200/jco-25-02477
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25